188 related articles for article (PubMed ID: 8638026)
1. A perspective on the ESVEM trial current knowledge: sotalol should not be the first-line agent in the management of ventricular arrhythmias.
Garan H
Prog Cardiovasc Dis; 1996; 38(6):455-6. PubMed ID: 8638026
[TBL] [Abstract][Full Text] [Related]
2. Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring.
Reiffel JA; Hahn E; Hartz V; Reiter MJ
Am J Cardiol; 1997 Apr; 79(8):1048-53. PubMed ID: 9114762
[TBL] [Abstract][Full Text] [Related]
3. Sotalol: An important new antiarrhythmic.
Anderson JL; Prystowsky EN
Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
[TBL] [Abstract][Full Text] [Related]
4. Implications of the Electrophysiologic Study versus Electrocardiographic Monitoring trial for controlling ventricular tachycardia and fibrillation.
Reiffel JA
Am J Cardiol; 1996 Aug; 78(4A):34-40. PubMed ID: 8780327
[TBL] [Abstract][Full Text] [Related]
5. Evolving role of sotalol in the management of ventricular tachyarrhythmias.
O'Callaghan PA; McGovern BA
Am J Cardiol; 1996 Aug; 78(4A):54-60. PubMed ID: 8780329
[TBL] [Abstract][Full Text] [Related]
6. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
Lazzara R
Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of sotalol and class I antiarrhythmic agents in patients with ventricular tachycardia or fibrillation: results of the Electrophysiology Study Versus Electrocardiographic Monitoring (ESVEM) Trial.
Klein RC
Eur Heart J; 1993 Nov; 14 Suppl H():78-84. PubMed ID: 8293756
[TBL] [Abstract][Full Text] [Related]
8. Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest.
Haverkamp W; Eckardt L; Borggrefe M; Breithardt G
Am J Cardiol; 1997 Oct; 80(8A):67G-73G. PubMed ID: 9354413
[TBL] [Abstract][Full Text] [Related]
9. Management of patients with life-threatening sustained ventricular tachyarrhythmias--the role of guided antiarrhythmic drug therapy.
Steinbeck G; Greene HL
Prog Cardiovasc Dis; 1996; 38(6):419-28. PubMed ID: 8638023
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs].
Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G
Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989
[TBL] [Abstract][Full Text] [Related]
11. Beta-blockers for ventricular arrhythmias: have we underestimated their value?
Campbell TJ
Aust N Z J Med; 1996 Oct; 26(5):689-96. PubMed ID: 8958366
[No Abstract] [Full Text] [Related]
12. Electrocardiographic predictors in the ESVEM trial: unsustained ventricular tachycardia, heart period variability, and the signal-averaged electrocardiogram.
Anderson KP; Bigger JT; Freedman RA
Prog Cardiovasc Dis; 1996; 38(6):463-88. PubMed ID: 8638028
[TBL] [Abstract][Full Text] [Related]
13. Insights into the Electrophysiology Study Versus Electrocardiographic Monitoring Trial: its programmed stimulation protocol may introduce bias when assessing long-term antiarrhythmic drug therapy.
Biblo LA; Carlson MD; Waldo AL
J Am Coll Cardiol; 1995 Jun; 25(7):1601-4. PubMed ID: 7759711
[TBL] [Abstract][Full Text] [Related]
14. Is primary antiarrhythmic drug therapy for ventricular arrhythmias obsolete?
Cooley R; Akhtar M; Sra J
Curr Cardiol Rep; 1999 Nov; 1(4):268-73. PubMed ID: 10980853
[TBL] [Abstract][Full Text] [Related]
15. Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment.
Kühlkamp V; Mewis C; Mermi J; Bosch RF; Seipel L
J Am Coll Cardiol; 1999 Jan; 33(1):46-52. PubMed ID: 9935007
[TBL] [Abstract][Full Text] [Related]
16. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
Bollmann A; Husser D; Cannom DS
Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
[TBL] [Abstract][Full Text] [Related]
17. Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia.
Antz M; Cappato R; Kuck KH
J Cardiovasc Pharmacol; 1995 Oct; 26(4):627-35. PubMed ID: 8569226
[TBL] [Abstract][Full Text] [Related]
18. Effect of amiodarone and sotalol on ventricular defibrillation threshold: the optimal pharmacological therapy in cardioverter defibrillator patients (OPTIC) trial.
Hohnloser SH; Dorian P; Roberts R; Gent M; Israel CW; Fain E; Champagne J; Connolly SJ
Circulation; 2006 Jul; 114(2):104-9. PubMed ID: 16818810
[TBL] [Abstract][Full Text] [Related]
19. Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.
AbdelWahab A; Sapp J
Curr Cardiol Rep; 2017 Sep; 19(11):105. PubMed ID: 28900864
[TBL] [Abstract][Full Text] [Related]
20. The role of EP-guided therapy in ventricular arrhythmias: beta-blockers, sotalol, and ICD's.
Capucci A; Aschieri D; Villani GQ
J Interv Card Electrophysiol; 2000 Jan; 4 Suppl 1():57-63. PubMed ID: 10590490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
